Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019927 | 0.92 | LSS (0.51) | LSSCHRNA7CHRM2CHRM1 | |
| SCHEMBL3229552 | 0.86 | CHRNA7 (0.68) | LSSCHRNA7CHRM1 | |
| SCHEMBL3229549 | 0.86 | CHRNA7 (0.68) | LSSCHRNA7CHRM1 | |
| SCHEMBL5390772 | 0.86 | LSS (0.60) | LSSCHRNA7 | |
| SCHEMBL13495086 | 0.84 | CHRNB2 (0.48) | LSSCHRNA7 | |
| SCHEMBL9469879 | 0.84 | CHRNB2 (0.48) | LSSCHRNA7 | |
| SCHEMBL1849257 | 0.83 | LSS (0.57) | LSSCHRNA7CHRM2CHRM4CHRM5 | |
| SCHEMBL2323165 | 0.83 | LSS (0.57) | LSSCHRNA7 | |
| SCHEMBL3215152 | 0.83 | LSS (0.78) | LSSCHRNA7 | |
| SCHEMBL3215158 | 0.83 | LSS (0.78) | LSSCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030138376-A1 | Dosing form for reagents, use of said dosing form in organic chemical synthesis and production of said dosing form | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| EP-1268051-A2 | DOSING FORM FOR REAGENTS, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND PRODUCTION OF SAID DOSING FORM | H. Lundbeck A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001068599-A2 | DOSING FORM FOR REAGENTS, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND PRODUCTION OF SAID DOSING FORM | H. LUNDBECK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
| US-5258392-A | 3-quinuclidine derivatives | AKZO N.V. (NL) | 1993-11-02 | — | — | US | disclosed |
| EP-0497415-A1 | 3-Quinuclidine derivatives | Akzo Nobel N.V. (NL) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138376-A1 | Dosing form for reagents, use of said dosing form in organic chemical synthesis and production of said dosing form | ATIC, SET, SORD | LSS 643/4885CHRNA7 4549/4885CHRM2 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.